2025
Carfilzomib or bortezomib with lenalidomide, and dexamethasone (VRd) for initial therapy of newly diagnosed multiple myeloma (NDMM): Long-term follow-up of the ECOG-ACRIN ENDURANCE phase 3 trial.
Kumar S, Faber E, Cohen A, Callander N, Singh A, Parker T, Menter A, Yang X, Parsons B, Kumar P, Kapoor P, Aaron R, Zonder J, Anderson K, Lonial S, Richardson P, Orlowski R, Wagner L, Rajkumar S, Jacobus S. Carfilzomib or bortezomib with lenalidomide, and dexamethasone (VRd) for initial therapy of newly diagnosed multiple myeloma (NDMM): Long-term follow-up of the ECOG-ACRIN ENDURANCE phase 3 trial. Journal Of Clinical Oncology 2025, 43: 7540-7540. DOI: 10.1200/jco.2025.43.16_suppl.7540.Peer-Reviewed Original ResearchNewly diagnosed myelomaProgression free survivalPhase 3 trialTreatment of newly diagnosed myelomaMedian progression free survivalRandomized phase 3 trialNewly diagnosed multiple myelomaLong-term follow-upProteasome inhibitorsBortezomib (VPlasma cell leukemiaLong-term resultsIntent to transplantR-maintenanceOS probabilityMedian followFree survivalInduction regimenCell leukemiaMedian ageSurvival outcomesMultiple myelomaInitial treatmentBaseline characteristicsFollow-upAssociation between patient demographics and smoldering multiple myeloma progression to multiple myeloma: A SEER-Medicare data analysis
Theprungsirikul P, Wang R, Ahmad I, Neparidze N, Ma X, Chang S, Wang S. Association between patient demographics and smoldering multiple myeloma progression to multiple myeloma: A SEER-Medicare data analysis. Clinical Lymphoma Myeloma & Leukemia 2025 DOI: 10.1016/j.clml.2025.06.016.Peer-Reviewed Original ResearchSmoldering multiple myelomaSmoldering multiple myeloma patientsMultiple myelomaPatient demographicsProgression to multiple myelomaSymptomatic multiple myelomaDevelopment of hypercalcemiaCox proportional hazards modelsRisk stratification modelConfidence intervalsNon-cancer controlsEstimate hazard ratiosProportional hazards modelNon-cancer patientsSymptomatic MMRandom sample of Medicare beneficiariesSMM patientsRenal failureAnalyzed SurveillanceSEER-MedicareNatural history modelHazard ratioBone diseasePatientsSample of Medicare beneficiariesCRISPR-Cas13d Functional Transcriptomics Reveals Widespread Isoform-Selective Cancer Dependencies on LncRNAs
Morelli E, Aktas Samur A, Maisano D, Gao C, Favasuli V, Papaioannou D, De Nola G, Henninger J, Liu N, Turi M, Folino P, Vreux L, Cumerlato M, Chen L, Aifantis I, Fulciniti M, Anderson K, Lytton-Jean A, Gulla A, Young R, Samur M, Munshi N. CRISPR-Cas13d Functional Transcriptomics Reveals Widespread Isoform-Selective Cancer Dependencies on LncRNAs. Blood 2025 PMID: 40403231, DOI: 10.1182/blood.2025028746.Peer-Reviewed Original ResearchCRISPR-Cas13dMultiple myelomaTE-lncRNAsIsoform-specific functionsDiverse cancer cell linesMM patientsCancer cell linesCellular proteostasisSubcellular localizationTumor cellsClinical dataCancer transcriptomeCytosolic isoformEndoplasmic reticulumFunctional transcriptomeHeat shock proteinsCancer dependenciesMM-specificClinical relevanceAnimal modelsLong noncoding RNAsLncRNA transcriptomeTherapeutic potentialCharacterize hundredsTranscriptomeHigh-Deductible Health Plans and Out-of-Pocket Health Care Costs Among Younger Patients With Multiple Myeloma.
Fiala M, Ji M, Slade M, Huber J, Shih Y, Wang M, Colditz G, Wang S, Vij R, Chang S. High-Deductible Health Plans and Out-of-Pocket Health Care Costs Among Younger Patients With Multiple Myeloma. JCO Oncology Practice 2025, op2400978. PMID: 40354593, DOI: 10.1200/op-24-00978.Peer-Reviewed Original ResearchStem-cell transplantationMultiple myelomaTreatment initiationHigh-deductible health plan enrollmentHigh-deductible health plansTransplant receiptShorter time to treatment initiationTime to treatment initiationOOP costsHealth Insurance DatabaseAssociated with delayStatistically significant differenceHealth plansPlan enrolleesOut-of-pocket health care costsYounger patientsOut-of-pocket (OOP) costsCox regressionPrimary outcomeMultivariate analysisSecondary outcomesInsurance DatabasePatientsTotal health careHealth care costsTeclistamab versus B-cell maturation antigen-targeting chimeric antigen receptor T-cell therapy in multiple myeloma: a comparative effectiveness analysis.
Song J, Chiang C, Esagian S, Kim G, Chi K, Chang Y, Parker T, Mehta A. Teclistamab versus B-cell maturation antigen-targeting chimeric antigen receptor T-cell therapy in multiple myeloma: a comparative effectiveness analysis. Haematologica 2025 PMID: 40207713, DOI: 10.3324/haematol.2024.287215.Peer-Reviewed Original ResearchFeasibility and Safety of Outpatient Model for Administration of Bispecific Antibodies: Proceedings from an International Myeloma Society 21st Annual Meeting Oral Abstract
Scott S, Roberts D, Gupta V, Joseph N, Hofmeister C, Dhodapkar M, Lonial S, Nooka A, Kaufman J. Feasibility and Safety of Outpatient Model for Administration of Bispecific Antibodies: Proceedings from an International Myeloma Society 21st Annual Meeting Oral Abstract. Clinical Lymphoma Myeloma & Leukemia 2025 PMID: 40345961, DOI: 10.1016/j.clml.2025.04.002.Peer-Reviewed Original ResearchStep-up dosingRelapsed/refractory multiple myelomaTarget doseInstitutional protocolRelapsed/refractory multiple myeloma patientsBispecific antibodiesTreatment of patientsProtocol eligibilityMultiple myelomaT cellsAccelerated approvalToxicity managementLower hospitalization ratesDay 1Low incidenceFDA labelingPatientsCare centerPatient's diseaseNeurological changesHospitalization ratesDoseOral abstractsTocilizumabHospitalStandard of Care Idecabtagene Vicleucel (Ide-cel) for Relapsed/Refractory Multiple Myeloma: A CIBMTR Analysis
Sidana S, Ahmed N, Akhtar O, Brazauskas R, Oloyede T, Bye M, Hansen D, Ferreri C, Freeman C, Afrough A, Anderson L, Dhakal B, Dhanda D, Gowda L, Hashmi H, Harrison M, Kitali A, Landau H, Mirza A, Patwardhan P, Qazilbash M, Usmani S, Patel K, Nishihori T, Ganguly S, Pasquini M. Standard of Care Idecabtagene Vicleucel (Ide-cel) for Relapsed/Refractory Multiple Myeloma: A CIBMTR Analysis. Blood 2025 PMID: 40198886, DOI: 10.1182/blood.2024026216.Peer-Reviewed Original ResearchCAR-T cell therapyStandard of careIde-celComplete responseIdecabtagene vicleucelMultiple myelomaImmune effector cell-associated neurotoxicity syndromeClinical trialsMedian progression-free survivalHigh-risk cytogeneticsProgression-free survivalT-cell therapyTreatment-related mortalityRelapsed/refractory multiple myelomaMedian follow-upClinically significant infectionsCytokine release syndromeSignificant co-morbiditiesSignificant co-morbidityEffects of standard of careExtramedullary diseaseCAR-TMyeloid malignanciesPrimary malignancyMedian ageBCL2 inhibition for multiple myeloma and AL amyloidosis
Cani L, Gupta V, Kaufman J. BCL2 inhibition for multiple myeloma and AL amyloidosis. British Journal Of Haematology 2025, 206: 1285-1296. PMID: 40090369, DOI: 10.1111/bjh.20046.Peer-Reviewed Original ResearchMultiple myelomaAL amyloidosisBCL2 inhibitorsLight-chain (ALTreatment landscape of MMPlasma cell disorderMalignant blood disordersDevelopment of novel treatmentsBCL2 inhibitionTreatment landscapeDose optimizationCell disordersPatient selectionClinical studiesBlood disordersNovel treatmentAmyloidosisBCL2Light chainMyelomaToxicity concernsPatientsInhibitorsDrugTreatmentAdvancements in minimally invasive interventional oncology procedures for painful sacral metastases under imaging guidance
Jiang W, Gan D, Johnson M, Latich I, Lee F. Advancements in minimally invasive interventional oncology procedures for painful sacral metastases under imaging guidance. EngMedicine 2025, 2: 100051. DOI: 10.1016/j.engmed.2024.100051.Peer-Reviewed Original ResearchPainful sacral metastasesIntra-operative image guidanceSacral metastasesImage guidancePreoperative baselineFollow-upPercutaneous interventionFunction scoresLong-term follow-upRisk of cement leakageO-arm navigationImprovement of painRetrospective cohort reviewImage guidance techniquesAverage follow-upInterventional oncology proceduresIntra-operative imaging techniquesO-armPercutaneous ablationSingle-institutionCohort reviewPrimary cancerClinical improvementMultiple myelomaCement leakageThe association between multiple myeloma and melanoma: a cross-sectional study of the NIH All of Us Research Program
Valido K, Murphy M, Langway J, Cohen J, Leventhal J, Deverapalli S. The association between multiple myeloma and melanoma: a cross-sectional study of the NIH All of Us Research Program. Archives Of Dermatological Research 2025, 317: 513. PMID: 40024923, DOI: 10.1007/s00403-025-04024-1.Peer-Reviewed Original ResearchCross-sectional studyMultiple myelomaHeme promotes venetoclax resistance in multiple myeloma through MEK-ERK signaling and purine biosynthesis
Nair R, Vu A, Freer A, Bhatia K, Wang D, Savani M, Matulis S, Lonial S, Jaye D, Boise L, Seo S, Corson T, Nooka A, Bhatt S, McBrayer S, Gupta V, Hu X, Barwick B, Reddi A, Shanmugam M. Heme promotes venetoclax resistance in multiple myeloma through MEK-ERK signaling and purine biosynthesis. Blood 2025, 145: 732-747. PMID: 39693611, PMCID: PMC12060166, DOI: 10.1182/blood.2024025690.Peer-Reviewed Original ResearchConceptsElectron transport chainBcl-2Heme biosynthesisBCL-2 antagonismElectron transport chain activityIron-containing prosthetic groupMultiple myelomaB-cell lymphoma 2MEK-ERK signalingGene signatureActivation of prosurvivalApoptotic thresholdPurine biosynthesisPenultimate enzymePyrimidine biosynthesisMetabolic rewiringTransport chainProtein kinaseMultiple Myeloma Research Foundation CoMMpass studyBiosynthesisPurine synthesisGenetic profilePrimary MM cellsProsthetic groupProgression-free survivalLong-Term Benefits in Patient-Reported Outcomes and Time to Next Anti-Myeloma Therapy of Ciltacabtagene Autoleucel (Cilta-cel) Versus Standard of Care for Patients with Lenalidomide-Refractory Multiple Myeloma: Results from the Phase 3 Cartitude-4 Clinical Trial
Bar N, Mina R, Mylin A, Yokoyama H, Magen H, Alsdorf W, Minnema M, Shune L, Isufi I, Harrison S, Shah U, De Champlain A, Gries K, Chen D, Li Q, Yeh T, Slaughter A, Lonardi C, Benachour N, Ghosh A, Deraedt W, Vogel M, Lendvai N, Patel N, Filho O, Florendo E, Karlin L, Weisel K. Long-Term Benefits in Patient-Reported Outcomes and Time to Next Anti-Myeloma Therapy of Ciltacabtagene Autoleucel (Cilta-cel) Versus Standard of Care for Patients with Lenalidomide-Refractory Multiple Myeloma: Results from the Phase 3 Cartitude-4 Clinical Trial. Transplantation And Cellular Therapy 2025, 31: s404-s405. DOI: 10.1016/j.jtct.2025.01.623.Peer-Reviewed Original ResearchAnti-myeloma therapyLenalidomide-refractory multiple myelomaMedian follow-upCilta-celProgressive diseaseMultiple myelomaStandard of careFollow-upCiltacabtagene autoleucelProgression-free survivalYears of follow-upKaplan-Meier methodCox proportional hazards modelsWorsening of symptomsProportional hazards modelPatient-reported outcomesEuropean Organization for ResearchOverall survivalProlonged survivalImmunomodulatory agentsSOC armGlobal health status/quality of lifeAnchor-based approachClinical trialsLong-term benefitsCiltacabtagene Autoleucel (Cilta-cel) Vs Standard of Care (SoC) in Patients with Lenalidomide (Len)-Refractory Multiple Myeloma (MM) after 1–3 Lines of Therapy: Minimal Residual Disease (MRD) Negativity in the Phase 3 Cartitude-4 Trial
Popat R, Oriol A, Cavo M, Karlin L, Avivi I, Roeloffzen W, Kim S, Lipe B, Bar N, Horvath N, Spencer A, Min C, Chen D, Li Q, Li K, Slaughter A, Lonardi C, Benachour N, Ghosh A, Vogel M, Lendvai N, Lengil T, Patel N, Filho O, Florendo E, Lin Y. Ciltacabtagene Autoleucel (Cilta-cel) Vs Standard of Care (SoC) in Patients with Lenalidomide (Len)-Refractory Multiple Myeloma (MM) after 1–3 Lines of Therapy: Minimal Residual Disease (MRD) Negativity in the Phase 3 Cartitude-4 Trial. Transplantation And Cellular Therapy 2025, 31: s35. DOI: 10.1016/j.jtct.2025.01.047.Peer-Reviewed Original ResearchMinimal residual disease negativityMRD-negativity ratesMinimal residual diseaseProgression-free survivalCilta-cel infusionSustained MRD negativityCilta-celMRD negativityOverall survivalMultiple myelomaSOC armMinimal residual disease positivityMedian progression-free survivalInterim analysisStandard of careMedian OSComplete responseMRD evaluationResidual diseaseCiltacabtagene autoleucelBridging therapyPost-infusionNext-generation sequencingTherapyInfusionPatient-reported outcomes following ciltacabtagene autoleucel or standard of care in patients with lenalidomide-refractory multiple myeloma (CARTITUDE-4): results from a randomised, open-label, phase 3 trial
Mina R, Mylin A, Yokoyama H, Magen H, Alsdorf W, Minnema M, Shune L, Isufi I, Harrison S, Shah U, Schecter J, Vogel M, Lendvai N, Gries K, Katz E, Slaughter A, Lonardi C, Gilbert J, Li Q, Deraedt W, Filho O, Patel N, Florendo E, Karlin L, Weisel K. Patient-reported outcomes following ciltacabtagene autoleucel or standard of care in patients with lenalidomide-refractory multiple myeloma (CARTITUDE-4): results from a randomised, open-label, phase 3 trial. The Lancet Haematology 2025, 12: e45-e56. PMID: 39756844, DOI: 10.1016/s2352-3026(24)00320-x.Peer-Reviewed Original ResearchConceptsLenalidomide-refractory multiple myelomaStandard of careVisual analogue scaleMultiple myelomaGlobal health statusPatient-reported outcomesCiltacabtagene autoleucelIntention-to-treat populationLenalidomide-refractory diseaseProgression-free survivalECOG performance statusPhase 3 trialEORTC global health statusWorsening of symptomsClinically meaningful improvementsEuropean Organisation for ResearchEQ-5D-5L visual analogue scaleCilta-celEuroQol 5-Dimension 5-LevelOpen-labelImmunomodulatory drugsMedian agePerformance statusSecondary endpointsClinical efficacy
2024
Associations Between Patient Characteristics and Progression to Multiple Myeloma Among Patients With Monoclonal Gammopathy of Undetermined Significance: A Systematic Review
Li Y, Hsu S, Wang R, Theprungsirikul P, Neparidze N, Chang S, Wang S. Associations Between Patient Characteristics and Progression to Multiple Myeloma Among Patients With Monoclonal Gammopathy of Undetermined Significance: A Systematic Review. Clinical Lymphoma Myeloma & Leukemia 2024, 25: e222-e231. PMID: 39730300, PMCID: PMC11911095, DOI: 10.1016/j.clml.2024.12.006.Peer-Reviewed Original ResearchProgression to MMMultiple myelomaNewcastle-Ottawa ScaleMonoclonal gammopathyRisk of progression to MMIncreased riskProgression to multiple myelomaRisk estimatesHigher body mass indexPre-malignant conditionBody mass indexRandom-effects modelMass indexCohort studyPatient characteristicsFemale sexMale genderMethodological qualityNewcastle-OttawaBlack raceRisk ratioMGUSRisk factorsPublication biasSystematic reviewUncommon biphasic CAR-T expansion induces hemophagocytic lymphohistiocytosis-like syndrome and fatal multiple infections following BCMA CAR-T cell therapy: a case report
Yan W, Xiong Y, Lv R, Du C, Yu T, Zhang S, Sui W, Deng S, Xiao J, Xu Y, Zou D, Qiu L, An G. Uncommon biphasic CAR-T expansion induces hemophagocytic lymphohistiocytosis-like syndrome and fatal multiple infections following BCMA CAR-T cell therapy: a case report. Journal For ImmunoTherapy Of Cancer 2024, 12: e010080. PMID: 39608976, PMCID: PMC11603806, DOI: 10.1136/jitc-2024-010080.Peer-Reviewed Original ResearchConceptsCAR-T expansionMultiple myelomaCell infusionSevere toxicityChimeric antigen receptor (CAR)-T-cell therapyCAR-T cell infusionCAR-T cell therapyMesenchymal stem cell infusionCentral nervous system infectionCell expansion in vivoAnti-infective regimenRefractory multiple myelomaCytokine release syndromeStem cell infusionImmune cell componentsNervous system infectionCases of patientsExpansion in vivoImproving cytopeniasCytomegalovirus viremiaCAR-TSpectral flow cytometryPolymicrobial infectionsCase reportStandard treatmentReal-World Efficacy and Patient-Reported Quality of Life Outcomes with Daratumumab Regimens in Multiple Myeloma
Browning S, Li F, Theprungsirikul P, Parker T, Bar N, Giri S, Anderson T, Stevens E, Gorshein E, Sabbath K, Wei C, Ali S, Witt D, Persico J, Talsania A, Rahmat L, Kidwai W, Legare R, LaSala J, Austin M, Neparidze N. Real-World Efficacy and Patient-Reported Quality of Life Outcomes with Daratumumab Regimens in Multiple Myeloma. Blood 2024, 144: 7831. DOI: 10.1182/blood-2024-204150.Peer-Reviewed Original ResearchRelapsed/refractory multiple myelomaInternational Myeloma Working GroupAdverse eventsGlobal health statusFunctional scalesMultiple symptom scalesPartial responseProteasome inhibitorsMultiple myelomaHealth statusEastern Cooperative Oncology Group performance statusClinical trialsMonoclonal antibody targeting CD38Median progression free survivalRelapsed/refractory multiple myeloma patientsIntroduction of novel therapiesHealth-related quality of lifeClinical response assessmentDaratumumab-based regimensProgression free survivalInfusion-related reactionsLines of therapyPatient-reported quality of life outcomesMean fatigue scoreHealth-related qualityA Randomized Trial Demonstrates a 3-Shot Flu Vaccine Series Improves Protection over a Single Shot in Multiple Myeloma
Hofmeister C, Gupta V, Kaufman J, Nooka A, Joseph N, Lonial S, Dhodapkar M. A Randomized Trial Demonstrates a 3-Shot Flu Vaccine Series Improves Protection over a Single Shot in Multiple Myeloma. Blood 2024, 144: 255-255. DOI: 10.1182/blood-2024-202102.Peer-Reviewed Original ResearchPlasma cell disorderStandard armInfluenza vaccineMyeloma patientsIntensive armDaratumumab exposureRandomized controlled trialsMultiple myelomaFlu seasonCell disordersHistory of severe allergic reactionsStandard-dose influenza vaccinesTreat analysisRisk of influenza-like illnessT-cell engagersSeasonal influenza vaccineHigh dose vaccineHigh dose injectionsInfluenza-like illnessProportion of patientsFlu vaccinationVaccine preventable illnessYears of ageSevere allergic reactionsStatistically significant differenceGenomic Determinants of Clinical Outcomes in Multiple Myeloma with t(11;14)(CCND1;IGH) Treated with Venetoclax
Kaddoura M, Wiedmeier-Nutor J, Gupta V, Ziccheddu B, Shivaram S, Tang H, Fonseca R, Durante M, Matulis S, Jelinek T, Landgren O, Mitsiades C, Bergsagel P, Braggio E, Boise L, Fonseca R, Kumar S, Maura F, Baughn L. Genomic Determinants of Clinical Outcomes in Multiple Myeloma with t(11;14)(CCND1;IGH) Treated with Venetoclax. Blood 2024, 144: 249. DOI: 10.1182/blood-2024-204071.Peer-Reviewed Original ResearchProgression free survivalSingle nucleotide variantsWhole-genome sequencingMultiple myelomaMM patientsFocal deletionsCopy number variantsMechanisms of resistanceTraining cohortValidation cohortChronic lymphocytic leukemia treated with venetoclaxDisease progressionMAPK pathwayMedian progression free survivalPopulation of MM patientsDeterminants of clinical outcomeAnti-CD38 agentsTreated with venetoclaxComprehensive genomic profilingMAPK pathway mutationsStructural variantsAcute myeloid leukemiaGenomic eventsLoss of NoxaNovel drug combinationsThe Role of NOXA in Venetoclax Treatment Response in Multiple Myeloma
Shivaram S, Yan H, Tang H, Anderson H, Kaddoura M, Wiedmeier-Nutor J, Tian S, Howe M, Bolarinwa A, Zepeda Mendoza C, Gupta V, Lehman S, Mitsiades C, Bergsagel P, Braggio E, Boise L, Fonseca R, Maura F, Kumar S, Baughn L. The Role of NOXA in Venetoclax Treatment Response in Multiple Myeloma. Blood 2024, 144: 4635-4635. DOI: 10.1182/blood-2024-205385.Peer-Reviewed Original ResearchMayo Clinic cohortNoxa proteinMultiple myelomaG alleleIncreased expressionGene expressionCyclin D1Clinical cohortExpression of CCND1Cell linesAllele specific effectsBCL-2 inhibitor venetoclaxLevels of NoxaHistone mark H3K27acG risk allelePrimary cytogenetic abnormalityPlasma cell malignancyAssociated with increased expressionRNA sequencing dataHuman myeloma cell linesKO cell linesWestern blottingAnalyzed whole-exomeChIP-seqWhole genome
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply